Biohaven Ltd

Bailey Gregory’s 68,693‑option purchase at Biohaven signals strong insider confidence amid volatility, hinting at future upside if the company’s pipeline progresses.

Biohaven insiders, led by Mehta Kishan, are buying zero‑cost options, signaling confidence ahead of 2026 NDA filings for Bavencio‑ALX and Bavencio‑L, and potential upside if approvals succeed.

Biohaven CFO’s $0 option grant signals confidence in its neurologic‑immunology pipeline, aligning leadership incentives with long‑term value and digital‑health‑driven reimbursement strategies.